Table 1.
Patient characteristics
| Characteristics | Values |
|---|---|
| Age (year), median (IQR) | 43 (20–85) |
| Gender (male), n (%) | 24 (73) |
| Ethnicity (Caucasian/Asian/African), n | 25/7/1 |
| BMI (kg/m2), mean ± SD | 25 ± 5 |
| SBP (mmHg), mean ± SD | 142 ± 18 |
| DBP (mmHg), mean ± SD | 87 ± 13 |
| Hypertension, n (%) | 16 (53) |
| History of macroscopic haematuria, n (%) | 5 (17) |
| Microscopic haematuria, n (%) | 30 (91) |
| Spot urine PCR (mg/mmol), median (IQR) | 120 (12–548) |
| <50, n | 5 |
| 50–99, n | 8 |
| 100–299, n | 12 |
| >300, n | 8 |
| eGFR (mL/min per 1.73 m2), mean ± SD | 55 ± 31 |
| CKD Stages 1–5, n | 5/7/14/4/3 |
| Oxford classification score MEST-C, n | |
| M 0/1 | 10/23 |
| E 0/1 | 27/6 |
| S 0/1 | 10/23 |
| T 0/1/2 | 16/10/7 |
| C 0/1/2 | 17/14/2 |
| Immunosuppression after diagnosis, n | 11 |
| ACE inhibitor or ARB (prior to/after diagnosis) | |
| ACE inhibitor | 3/15 |
| ARB | 5/7 |
| Dual blockade | 1/3 |
Results are presented as mean ± SD or median with range. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; M, mesangial hypercellularity; E, endocapillary hypercellularity; S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis.